Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2025-01-01
|
| Ráidu: | Leukemia Research Reports |
| Fáttát: | |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2213048925000317 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|